

<b>NCT ID</b>	NCT04776148
<b>Title</b>	Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
<b>Phase</b>	Phase 3
<b>Date Added</b>	2021-03-01
<b>Location</b>	California, United States Georgia, United States Illinois, United States Maryland, United States Michigan, United States Montana, United States Oregon, United States Pennsylvania, United States Virginia, United States Washington, United States Argentina Australia Canada China Denmark Germany Israel Japan Russia South Korea Spain Taiwan Turkey (Türkiye) United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Completed
<b>Drugs</b>	Lenvatinib, Pembrolizumab, Regorafenib, TAS-102 (trifluridine and tipiracil)
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT03947385
<b>Title</b>	Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2019-05-13
<b>Location</b>	California, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia Canada
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Binimetinib, Crizotinib, IDE196
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT05838768
<b>Title</b>	Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
<b>Phase</b>	Phase 1
<b>Date Added</b>	2023-05-03

<b>Location</b>	California, United States
	Massachusetts, United States
	New York, United States
	Texas, United States
	Belgium
	China
	France
	Germany
	Israel
	Italy
	Japan
	Norway
	Singapore
	South Korea
	Spain
	Sweden
	Taiwan
	United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	HRO761, Irinotecan
<b>Tags</b>	MSI-H/ MMRd
<hr/>	
<b>NCT ID</b>	NCT04092673
<b>Title</b>	Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
<b>Phase</b>	Phase 1
<b>Date Added</b>	2019-09-17
<b>Location</b>	California, United States
	Michigan, United States
	Nevada, United States
	New Jersey, United States
	New York, United States
	Ohio, United States
	Texas, United States
	Virginia, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Recruiting
<b>Drugs</b>	eFT226, eFT226
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT03069469
<b>Title</b>	Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2017-03-03

<b>Location</b>	California, United States Colorado, United States Florida, United States Massachusetts, United States New York, United States Oregon, United States Tennessee, United States Australia Canada France Italy Netherlands Poland Spain United Kingdom
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	DCC-3014
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT03545815
<b>Title</b>	Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.
<b>Phase</b>	Phase 1
<b>Date Added</b>	2018-06-04
<b>Location</b>	China
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Recruiting
<b>Drugs</b>	anti-mesothelin CAR-T cells
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT03950154
<b>Title</b>	Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer
<b>Phase</b>	Phase 3
<b>Date Added</b>	2019-05-15
<b>Location</b>	China
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Bevacizumab Injection [Avastin], capecitabine, oxaliplatin, PD1-T cells
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT03170960
<b>Title</b>	Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
<b>Phase</b>	Phase 1
<b>Date Added</b>	2017-05-31

<b>Location</b>	Arizona, United States California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Kansas, United States Kentucky, United States Louisiana, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States Australia Belgium France Germany Italy Netherlands Spain United Kingdom
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Atezolizumab, Cabozantinib
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT04963283
<b>Title</b>	Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2021-07-15
<b>Location</b>	Colorado, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Cabozantinib, Nivolumab
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT05198934
<b>Title</b>	Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak 300)
<b>Phase</b>	Phase 3
<b>Date Added</b>	2022-01-20

<b>Location</b>	Alabama, United States
	California, United States
	District of Columbia, United States
	Florida, United States
	Georgia, United States
	Michigan, United States
	New York, United States
	North Carolina, United States
	Ohio, United States
	Pennsylvania, United States
	Tennessee, United States
	Texas, United States
	Australia
	France
	Germany
	Greece
	Italy
	Japan
	Mexico
	South Korea
	Spain
	Taiwan
	United Kingdom
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp